Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024).
George Shenouda, Luís Souhami(McGill University Health Centre), Jeffery A. Hall(McGill University), Amro Mohammad(McGill University), Melissa Charbonneau(McGill University Health Centre), M. Perna(McGill University Health Centre), Bassam Abdulkarim(University of Alberta), Miguel Ángel Rodríguez Barrera(Goethe University Frankfurt), Valérie Panet-Raymond(McGill University Health Centre), Scott Owen(McGill University Health Centre), William Davalan(McGill University), Roberto J. Diaz(Montreal Neurological Institute and Hospital), Marie‐Christine Guiot(McGill University), Kevin Petrecca(McGill University Health Centre)
Cited by 3
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05
|International Journal of Radiation Oncology*Biology*Physics|2000|1.6k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k